このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Aptose Biosciences 将来の成長

Future 基準チェック /06

Aptose Biosciences の収益は、年間 4.5% 減少すると予測されています。EPS は、年間増加すると予測されています55.9%。

主要情報

-4.5%

収益成長率

55.9%

EPS成長率

Biotechs 収益成長	42.0%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	14 Jun 2024

今後の成長に関する最新情報

Recent updates

Companies Like Aptose Biosciences (TSE:APS) Are In A Position To Invest In Growth

Sep 30

Aptose Biosciences Inc. (TSE:APS) Insiders Have Been Selling

Feb 07

Is Aptose Biosciences Inc.'s (TSE:APS) Shareholder Ownership Skewed Towards Insiders?

Jan 03

We're Not Very Worried About Aptose Biosciences' (TSE:APS) Cash Burn Rate

Nov 29

Jotin Marango Is The Senior VP & Chief Business Officer of Aptose Biosciences Inc. (TSE:APS) And They Just Sold 26% Of Their Shares

Jul 11

Aptose Biosciences Inc. (TSE:APS) Insiders Have Been Selling

Jun 27

業績と収益の成長予測

TSX:APS - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	N/A	-51	N/A	N/A	2
12/31/2024	N/A	-44	N/A	N/A	3
3/31/2024	N/A	-47	-45	-45	N/A
12/31/2023	N/A	-51	-45	-45	N/A
9/30/2023	N/A	-49	-44	-44	N/A
6/30/2023	N/A	-48	-40	-40	N/A
3/31/2023	N/A	-44	-34	-34	N/A
12/31/2022	N/A	-42	-32	-32	N/A
9/30/2022	N/A	-56	-40	-40	N/A
6/30/2022	N/A	-58	-41	-41	N/A
3/31/2022	N/A	-61	-43	-43	N/A
12/31/2021	N/A	-65	-44	-43	N/A
9/30/2021	N/A	-56	-38	-38	N/A
6/30/2021	N/A	-58	-38	-38	N/A
3/31/2021	N/A	-60	-36	-36	N/A
12/31/2020	N/A	-55	-34	-34	N/A
9/30/2020	N/A	-48	-30	-30	N/A
6/30/2020	N/A	-42	-27	-27	N/A
3/31/2020	N/A	-32	-25	-25	N/A
12/31/2019	N/A	-26	-22	-22	N/A
9/30/2019	N/A	-25	-21	-21	N/A
6/30/2019	N/A	-24	-20	-20	N/A
3/31/2019	N/A	-28	-24	-24	N/A
12/31/2018	N/A	-29	-24	-23	N/A
9/30/2018	N/A	-26	-21	-21	N/A
6/30/2018	N/A	-23	-18	-18	N/A
3/31/2018	N/A	-15	-12	-12	N/A
12/31/2017	N/A	-12	N/A	-10	N/A
9/30/2017	N/A	-11	N/A	-10	N/A
6/30/2017	N/A	-12	N/A	-11	N/A
3/31/2017	N/A	-14	N/A	-12	N/A
12/31/2016	N/A	-14	N/A	-12	N/A
9/30/2016	N/A	-15	N/A	-12	N/A
6/30/2016	N/A	-14	N/A	-12	N/A
3/31/2016	N/A	-12	N/A	-12	N/A
1/1/2016	N/A	-12	N/A	-10	N/A
9/30/2015	N/A	-9	N/A	-8	N/A
12/31/2014	N/A	-12	N/A	-10	N/A
5/31/2014	N/A	-10	N/A	-8	N/A
2/28/2014	N/A	-7	N/A	-5	N/A
11/30/2013	N/A	-6	N/A	-4	N/A

アナリストによる今後の成長予測

収入対貯蓄率: APS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: APS今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: APS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: APSの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: APS来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: APSの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Aptose Biosciences 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Forecast to breakeven in 2025

Consensus forecasts updated

Consensus revenue estimates increase to US$928.6k

Recent updates

Aptose Biosciences Inc. has completed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

Aptose Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $4.43325 million.

New major risk - Financial position

Aptose Biosciences Inc. to Report Q1, 2024 Results on May 14, 2024

Aptose Biosciences Receives a Letter from the Nasdaq Stock Market Stating the Company Was Not in Compliance with Nasdaq Listing Rule 5550(b)(1)

New major risk - Negative shareholders equity

Aptose Biosciences Inc., Annual General Meeting, May 28, 2024

Aptose Biosciences Inc. to Report Q4, 2023 Results on Mar 26, 2024

Aptose Biosciences Receives Deficiency Letter from The Nasdaq Stock Market LLC

Aptose Biosciences Inc. announced that it has received $4 million in funding from Hanmi Pharm. Co., Ltd.

New major risk - Shareholder dilution

Aptose Biosciences Inc. has completed a Follow-on Equity Offering in the amount of $16.799998 million.

Aptose Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $16.799998 million.

Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

Aptose Biosciences Inc. Appoints Fletcher Payne as Chief Business Officer

New major risk - Financial position

Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting

Aptose Biosciences Inc. Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

New major risk - Share price stability

Aptose Biosciences Inc. to Report Q3, 2023 Results on Nov 09, 2023

Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th

Independent Director recently bought CA$72k worth of stock

Aptose Biosciences Inc. Provides A Recent Update from an Ongoing Aptivate Phase 1/2 Clinical Trial with the Company's Lead Agent, Tuspetinib

Aptose Biosciences Inc. announced that it expects to receive CAD 7 million in funding from Hanmi Science Co., Ltd.

New minor risk - Share price stability

Aptose Biosciences Inc. to Report Q2, 2023 Results on Aug 10, 2023

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

Aptose Biosciences Inc. Presents Highlights from Clinical Update

Aptose Biosciences Inc. announced that it expects to receive CAD 25 million in funding

Forecast to breakeven in 2025

Here's Why We're Watching Aptose Biosciences' (TSE:APS) Cash Burn Situation

Aptose Biosciences Inc. Updates Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations

We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate

Aptose Biosciences Inc. Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib

Insufficient new directors

Aptose Biosciences Inc. to Report Q3, 2022 Results on Nov 01, 2022

Aptose Biosciences Inc. Appoints Bernd R. Seizinger to the Board of Directors

Aptose Biosciences Inc.’s New G3 Formulation of Luxeptinib Boosts Bioavailability

We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate

Aptose Biosciences Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department Regarding Minimum Bid Price Requirement

Aptose Biosciences Inc. to Report Q2, 2022 Results on Aug 02, 2022

Aptose Appoints Fletcher Payne as Chief Financial Officer

Aptose Receives Fast Track Designation for Hm43239 in Relapsed/Refractory Aml Patients and Flt3 Mutation

Insufficient new directors

Aptose Biosciences Inc. to Report Q1, 2022 Results on May 09, 2022

Aptose Biosciences Inc. Announces Resignation of Dr. Jotin Marango as Chief Financial Officer

We Think Aptose Biosciences (TSE:APS) Needs To Drive Business Growth Carefully

Aptose Biosciences Inc. Provides Update on APTO-253 Program

Independent Director recently bought CA$408k worth of stock

Aptose Biosciences Inc. Announces HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia

Companies Like Aptose Biosciences (TSE:APS) Are In A Position To Invest In Growth

Insufficient new directors

Independent Director recently sold CA$83k worth of stock

Aptose Presents Highlights from EHA2021 Virtual Congress During Corporate Update Event

Consensus forecasts updated

Executive VP, Corporate Secretary, CFO & COO has left the company

Consensus revenue estimates increase to US$928.6k

Aptose Biosciences Inc. to Report Q4, 2020 Results on Mar 23, 2021

New 90-day low: CA$5.06

Aptose Biosciences Inc. (TSE:APS) Insiders Have Been Selling

Is Aptose Biosciences Inc.'s (TSE:APS) Shareholder Ownership Skewed Towards Insiders?

Independent Director exercised options and sold CA$53k worth of stock

New 90-day high: CA$9.13

We're Not Very Worried About Aptose Biosciences' (TSE:APS) Cash Burn Rate

Aptose Biosciences Inc. to Present CG-806 and APTO-253 Data At the 2020 Ash Annual Meeting

Aptose Biosciences Inc. to Report Q3, 2020 Results on Nov 10, 2020

New 90-day low: CA$6.30

Aptose Initiates Dosing of CG-806 in Patients with Acute Myeloid Leukemia

New 90-day low - CA$6.47

Aptose Biosciences Inc. to Report Q2, 2020 Results on Aug 04, 2020

Aptose Biosciences Inc. has completed a Follow-on Equity Offering in the amount of $55.125 million.